Basit öğe kaydını göster

To rechallenge or not to rechallenge, that is the question? An unsuccessful attempt of hypomethylating agent plus venetoclax in an elderly FLT3-positive relapsed acute myeloid leukemia patient after a yearlong period of remission

dc.contributor.authorSevindik, Ömür Gökmen
dc.contributor.authorMergen, Mahmut
dc.contributor.authorMergen, Sena
dc.contributor.authorMutlu, Yaşa Gül
dc.contributor.authorBalık Aydın, Berrin
dc.contributor.authorSerin, İstemi
dc.date.accessioned2022-10-24T11:51:19Z
dc.date.available2022-10-24T11:51:19Z
dc.date.issued2022en_US
dc.identifier.citationSevindik, Ö. G., Mergen, M., Mergen, S., Mutlu, Y. G., Balık Aydın, B. ve Serin, İ. (2022). To rechallenge or not to rechallenge, that is the question? An unsuccessful attempt of hypomethylating agent plus venetoclax in an elderly FLT3-positive relapsed acute myeloid leukemia patient after a yearlong period of remission. Annals of Hematology, 101(11), 2545-2547. https://doi.org/10.1007/s00277-022-04938-0en_US
dc.identifier.issn1432-0584
dc.identifier.issn0939-5555
dc.identifier.urihttps://doi.org/10.1007/s00277-022-04938-0
dc.identifier.urihttps://hdl.handle.net/20.500.12511/9872
dc.description.abstractDear Editor, Acute myeloid leukemia is the most common sub-type of acute leukemia in adulthood [1]. It has a detrimental prognosis with conventional combination chemotherapy, mainly with anthracyclines and cytarabine. Allogeneic stem cell transplantation has signifcantly prolonged the overall survival in a particular “eligible” patient population, but as AML is a disorder of the elderly, not all patients are able to proceed with allogeneic stem cell transplantation.en_US
dc.language.isoengen_US
dc.publisherSpringer Science and Business Media Deutschland GmbHen_US
dc.rightsinfo:eu-repo/semantics/openAccessen_US
dc.subjectHypomethylating Agenten_US
dc.subjectLeukemia Patienten_US
dc.subjectFlt3-Positive Relapsed Acute Myeloiden_US
dc.titleTo rechallenge or not to rechallenge, that is the question? An unsuccessful attempt of hypomethylating agent plus venetoclax in an elderly FLT3-positive relapsed acute myeloid leukemia patient after a yearlong period of remissionen_US
dc.typeletteren_US
dc.relation.ispartofAnnals of Hematologyen_US
dc.departmentİstanbul Medipol Üniversitesi, Tıp Fakültesi, Dahili Tıp Bilimleri Bölümü, İç Hastalıkları Ana Bilim Dalıen_US
dc.authorid0000-0001-9636-4113en_US
dc.authorid0000-0003-1508-2822en_US
dc.authorid0000-0001-6826-7818en_US
dc.identifier.volume101en_US
dc.identifier.issue11en_US
dc.identifier.startpage2545en_US
dc.identifier.endpage2547en_US
dc.relation.publicationcategoryDiğeren_US
dc.identifier.doi10.1007/s00277-022-04938-0en_US
dc.institutionauthorSevindik, Ömür Gökmen
dc.institutionauthorMergen, Mahmut
dc.institutionauthorMergen, Sena
dc.institutionauthorMutlu, Yaşa Gül
dc.institutionauthorBalık Aydın, Berrin
dc.identifier.wosqualityQ2en_US
dc.identifier.wos000832838100001en_US
dc.identifier.scopus2-s2.0-85139378137en_US
dc.identifier.pmid35906348en_US
dc.identifier.scopusqualityQ1en_US


Bu öğenin dosyaları:

Thumbnail
Ad:
Sevindik-Omur-2022.pdf
Boyut:
433.0Kb
Biçim:
PDF
Açıklama:
Tam Metin / Full Text
Göster/Aç

Bu öğe aşağıdaki koleksiyon(lar)da görünmektedir.

Basit öğe kaydını göster